• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IQVIA's SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award "Best Use of Artificial Intelligence in Healthcare"

    6/25/24 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $IQV alert in real time by email

    IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the "Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards.

    SmartSolve eQMS is part of IQVIA's suite of purpose-built safety, regulatory and quality technologies, providing a single source of truth for quality compliance. It is the first solution to simplify the complexity of quality compliance and offer a cross-functional, intelligent connection of regulatory and quality processes on a platform designed specifically for life sciences customers.

    SmartSolve eQMS's AI recommends the most appropriate problem code for the reporting of medical device adverse events and empowers quality operations to become a central hub for continuous improvement. With this streamlined process management, life sciences organizations have more time to focus on commercial, customer and compliance activities. As with all IQVIA AI-powered solutions, SmartSolve eQMS's AI capabilities are grounded in IQVIA Healthcare-grade AI™ – AI engineered to meet the level of precision, speed and trust required for life sciences and healthcare.

    "We are incredibly honored to be recognized by MedTech Breakthrough for our innovation in AI-powered healthcare solutions," said Susan Hill, vice president of Global Product Management, Digital Products & Solutions, IQVIA. "The addition of artificial intelligence capabilities within the SmartSolve platform accelerates and supports human decision-making in the provision of safe and effective care globally."

    The MedTech Breakthrough Awards are conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market. The mission of the Awards is to honor excellence and recognize the creativity, innovation, hard work and success of digital health and medical technology companies, services and products around the globe. This year's program attracted more than 4,500 nominations from all over the world.

    "The MedTech industry is facing a challenging quality environment with rapidly increasing complexity. The management of global regulations, technological advancements and country-by-country regulatory variations places immense strain on quality teams," said Steve Johansson, managing director, MedTech Breakthrough. "SmartSolve's innovative use of artificial intelligence enables the automation of administrative and transactional activities, allowing quality professionals to focus on critical, high-value tasks. The solution's recognition is well-deserved; congratulations to the IQVIA team."

    To learn more about the benefits of the IQVIA SmartSolve platform, visit our site.

    About IQVIA

    IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligence™ delivers actionable insights and powerful solutions with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

    IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240625276074/en/

    Get the next $IQV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IQV

    DatePrice TargetRatingAnalyst
    3/3/2026$221.00Outperform
    RBC Capital Mkts
    12/2/2025$265.00Overweight
    Morgan Stanley
    11/13/2025$260.00Outperform
    BMO Capital Markets
    11/3/2025$215.00Buy → Hold
    TD Cowen
    10/29/2025$258.00Neutral → Outperform
    Robert W. Baird
    10/9/2025$235.00Hold → Buy
    HSBC Securities
    9/9/2025$225.00Hold → Buy
    Jefferies
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $IQV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and he

    3/2/26 4:30:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intellige

    3/2/26 4:15:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Releases its 2025 Sustainability Report

    IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA's progress across its People, Public and Planet pillars, consistent with the company's mission to accelerate innovation for a healthier world. IQVIA's 2025 Sustainability Report can be downloaded at: https://www.iqvia.com/-/media/iqvia/pdfs/about-us/sustainability/iqvia-2025-sustainability-report.pdf. Highlights from the report include: Investments in the company's employees. IQVIA's approximately 93,000 employees worldwide are c

    2/27/26 4:47:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    SEC Filings

    View All

    SEC Form DEFA14A filed by IQVIA Holdings Inc.

    DEFA14A - IQVIA HOLDINGS INC. (0001478242) (Filer)

    2/27/26 4:54:04 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form DEF 14A filed by IQVIA Holdings Inc.

    DEF 14A - IQVIA HOLDINGS INC. (0001478242) (Filer)

    2/27/26 4:52:32 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by IQVIA Holdings Inc.

    10-K - IQVIA HOLDINGS INC. (0001478242) (Filer)

    2/17/26 7:46:53 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on IQVIA with a new price target

    RBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $221.00

    3/3/26 8:27:50 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Morgan Stanley resumed coverage on IQVIA with a new price target

    Morgan Stanley resumed coverage of IQVIA with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:26:39 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BMO Capital Markets initiated coverage on IQVIA with a new price target

    BMO Capital Markets initiated coverage of IQVIA with a rating of Outperform and set a new price target of $260.00

    11/13/25 9:14:20 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Haas Bernd covered exercise/tax liability with 20 shares, decreasing direct ownership by 0.08% to 24,394 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/17/26 5:01:48 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Officer Fedock Michael J. covered exercise/tax liability with 123 shares, decreasing direct ownership by 1% to 9,472 units (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/17/26 5:01:10 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Officer Staub W Richard

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/11/26 5:11:44 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/7/25 7:03:59 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Financials

    Live finance-specific insights

    View All

    IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year GAAP Net Income of $514 million for the fourth quarter, $1,360 million for the full year Adjusted EBITDA of $1,046 million for the fourth quarter, $3,788 million for the full year GAAP Diluted Earnings per Share of $2.99 for the fourth quarter, $7.84 for the full year Adjusted Diluted Earnings per Share of $3.42 for the fourth quarter, $11.92 for the full year R&D Solutions quarterly bookings of over $2.7 billion, representing a book-to-bill ratio of 1.18x R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year R&D Solutions Revenue of $2,333 million for the fourth qua

    2/5/26 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http:/

    1/20/26 4:45:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Reports Third-Quarter 2025 Results

    Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to

    10/28/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Leadership Updates

    Live Leadership Updates

    View All

    IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    9/25/23 8:01:00 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    6/7/22 8:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    3/14/22 9:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $IQV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/15/24 7:57:23 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by IQVIA Holdings Inc.

    SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)

    2/14/24 4:11:54 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by IQVIA Holdings Inc. (Amendment)

    SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    1/25/24 4:59:33 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care